DOI:
10.1055/s-00000167
International Journal of Angiology
LinksClose Window
References
Zelniker TA, Wiviott SD, Raz I. et al.
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Lancet 2019;
393 (10166): 31-39
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.